An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients With Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Goserelin (Primary) ; Letrozole (Primary) ; Palbociclib (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- 14 Jan 2019 Planned End Date changed from 1 Oct 2022 to 1 Nov 2022.
- 14 Jan 2019 Planned primary completion date changed from 1 Oct 2021 to 1 Nov 2021.
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.